Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
Vizzotti C, Harris JB, Aquino A, Rancaño C, Biscayart C, Bonaventura R, Pontoriero A, Baumeister E, Freire MC, Magariños M, Duarte B, Grant G, Reef S, Laven J, Wannemuehler KA, Alvarez AMR, Staples JE. Vizzotti C, et al. BMC Infect Dis. 2023 Mar 17;23(1):165. doi: 10.1186/s12879-023-08114-1. BMC Infect Dis. 2023. PMID: 36932346 Free PMC article. Clinical Trial.
Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.
Perez-Vilar S, Weibel D, Sturkenboom M, Black S, Maure C, Castro JL, Bravo-Alcántara P, Dodd CN, Romio SA, de Ridder M, Nakato S, Molina-León HF, Elango V, Zuber PLF; WHO Global Vaccine Safety-Multi Country Collaboration. Perez-Vilar S, et al. Vaccine. 2018 Jan 8;36(3):347-354. doi: 10.1016/j.vaccine.2017.05.012. Epub 2017 May 27. Vaccine. 2018. PMID: 28558983 Free PMC article.
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
Biscayart C, Carrega ME, Sagradini S, Gentile A, Stecher D, Orduna T, Bentancourt S, Jiménez SG, Flynn LP, Arce GP, Uboldi MA, Bugna L, Morales MA, Digilio C, Fabbri C, Enría D, Diosque M, Vizzotti C. Biscayart C, et al. Among authors: vizzotti c. Vaccine. 2014 Mar 5;32(11):1266-72. doi: 10.1016/j.vaccine.2014.01.015. Epub 2014 Jan 21. Vaccine. 2014. PMID: 24456625
Influenza vaccine effectiveness against hospitalizations in children and older adults-Data from South America, 2013-2017. A test negative design.
Sofia Arriola C, El Omeiri N, Azziz-Baumgartner E, Thompson MG, Sotomayor-Proschle V, Fasce RA, Von Horoch M, Enrique Carrizo Olalla J, Aparecida Ferreira de Almeida W, Palacios J, Palekar R, Couto P, Descalzo M, María Ropero-Álvarez A; REVELAC-I network participants. Sofia Arriola C, et al. Vaccine X. 2019 Nov 2;3:100047. doi: 10.1016/j.jvacx.2019.100047. eCollection 2019 Dec 10. Vaccine X. 2019. PMID: 31867577 Free PMC article.
Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative.
Guillard-Maure C, Elango V, Black S, Perez-Vilar S, Castro JL, Bravo-Alcántara P, Molina-León HF, Weibel D, Sturkenboom M, Zuber PLF; WHO Global Vaccine Safety-Multi Country Collaboration. Guillard-Maure C, et al. Vaccine. 2018 Jan 8;36(3):355-362. doi: 10.1016/j.vaccine.2017.07.085. Epub 2017 Aug 2. Vaccine. 2018. PMID: 28780118
47 results